Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial - Associated Press

Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial  Associated Press

LIQ861was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDA -- NDA submission targeted for late 2019 ...



Comments

Popular posts from this blog

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country - Nasdaq

Clinical Management and Transplant Considerations in Pediatric Pulmonary Hypertension Due to Left Heart Disease: A Scientific Statement From the American Heart Association